APP下载

紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效

2020-06-19李博

医学信息 2020年10期
关键词:顺铂紫杉醇

李博

摘要:目的  研究紫杉醇加顺铂治疗晚期老年非小细胞癌临床疗效。方法  选取2017年3月~2018年3月在我院治疗的94例晚期老年非小细胞癌患者为研究对象,采用随机数字表法分为对照组和观察组,各47例。对照组采用顺铂治疗,观察组在对照组基础上加用紫杉醇,比较两组临床治疗总有效率、免疫功能指标(CD4、CD8、CD4/CD8)、生存率(10个月、20个月)以及毒副反应(白细胞减少、消化道反应、肝肾功能异常、血小板降低)发生情况。结果  观察组治疗总有效率为82.97%,高于对照组的72.34%(P<0.05);治疗后两组免疫功能指标CD4、CD8、CD4/CD8均高于治疗前,且观察组高于对照组(P<0.05);观察组生存率高于对照组(P<0.05);观察组毒副反应发生率为17.02%,与对照组的19.14%比较,差异无统计学意义(P>0.05)。结论  紫杉醇加顺铂治疗晚期老年非小细胞癌有效率高,有助于提高患者免疫功能,促进治疗耐受性,增加患者的生存时间,且毒副反应少,具有重要的临床应用价值。

关键词:紫杉醇;顺铂;晚期;非小细胞癌

Abstract:Objective  To study the clinical efficacy of paclitaxel plus cisplatin in the treatment of advanced elderly non-small cell carcinoma. Methods  94 patients with advanced non-small cell carcinoma who were treated in our hospital from March 2017 to March 2018 were selected as the research object. They were divided into a control group and an observation group with a random number table method, each with 47 cases. The control group was treated with cisplatin. The observation group was added paclitaxel on the basis of the control group. The total clinical efficacy, immune function indexes (CD4, CD8, CD4/CD8) and survival rate (10 months, 20 months) of the two groups were compared and the occurrence of side effects (leukopenia, gastrointestinal reactions, liver and kidney dysfunction, platelet reduction).Results  The total effective rate of treatment in the observation group was 82.97%, higher than 72.34% in the control group(P<0.05); after treatment, the immune function indexes CD4, CD8, CD4/CD8 of both groups were higher than before treatment, and the observation group was higher than the control group(P<0.05); the survival rate of the observation group was higher than the control group(P<0.05); the incidence of side effects in the observation group was 17.02%, and compared with 19.14% of the control group, the difference was not statistically significant (P>0.05).Conclusion  Paclitaxel plus cisplatin is highly effective in the treatment of advanced non-small cell carcinoma of the elderly. It can help improve the immune function of patients, promote treatment tolerance, increase the survival time of patients, and have fewer toxic and side reactions.

Key words:Paclitaxel;Cisplatin;Advanced stage;Non-small cell carcinoma

非小細胞癌(non-small cell carcinoma)是临床常见恶性肿瘤,患者在确诊时多处于局部晚期或伴有转移,可手术者较少,多需进行化疗。同步化疗可提高非小细胞癌的局部控制率和生存率,是当前治疗非小细胞癌的主要方法,但是化疗药物会增加患者的放射毒副反应,影响临床治疗依从性。顺铂是临床常用治疗非小细胞癌的药物,主要通过破坏DNA的功能,实现抑制细胞分裂的作用,但是患者毒副反应多,影响临床治疗效果[1]。紫杉醇主要是属于植物来源的抗癌药物,研究显示,该药与顺铂联合治疗老年非小细胞癌,两种药物相互协同,可一定程度改善肿瘤控制效果。本研究结合我院治疗的94例晚期老年非小细胞癌患者临床资料,分析紫杉醇加顺铂治疗晚期老年非小细胞癌疗效,现报道如下。……

登录APP查看全文

猜你喜欢

顺铂紫杉醇
电压门控离子通道参与紫杉醇所致周围神经病变的研究进展
心肌缺血预适应在紫杉醇释放冠脉球囊导管扩张术中的应用
紫杉醇脂质体与紫杉醇不同途径灌注治疗兔舌癌的疗效研究
脂质体紫杉醇周疗方案与普通紫杉醇治疗乳腺癌的疗效及不良反应比较
细胞自噬与人卵巢癌细胞对顺铂耐药的关系
紫杉醇联合顺铂冶疗食管癌的效果观察
奈达铂与顺铂同步放化疗治疗中晚期宫颈癌的疗效差异
吉西他滨联合顺铂治疗晚期三阴乳腺癌的疗效观察
护理干预对预防紫杉醇过敏反应疗效观察
紫杉醇新剂型的研究进展